Home » Authors » Brady Huggett

Brady Huggett

Articles

ARTICLES

$43.9M Series C Gives XenoPort Active Transport Program Funds

June 4, 2002

By Brady Huggett

XenoPort Inc. came off the financing trail with a $43.9 million Series C under it arm - its largest round to date. (BioWorld Today)

Agennix Raises $20M Privately, Prepares For Clinical Explosion

May 31, 2002

By Brady Huggett

Agennix Raises $20M Privately, Prepares For Clinical Explosion

May 31, 2002

By Brady Huggett

Paratek Raises $30M In Series D To Move First Product Into Clinic

May 29, 2002

By Brady Huggett

Paratek Raises $30M In Series D To Move First Product Into Clinic

May 29, 2002

By Brady Huggett

GlycoDesign Ends GD0039 Trials, Moving Focus To Other Programs

May 28, 2002

By Brady Huggett

GlycoDesign Ends GD0039 Trials, Moving Focus To Other Programs

May 28, 2002

By Brady Huggett

UTC's Remodulin Approved; Product Hits Market Running

May 24, 2002

By Brady Huggett

UTC's Remodulin Approved; Product Hits Market Running

May 24, 2002

By Brady Huggett

Biogen's Amevive Before Panel Today; FDA Hints At New Trials

May 23, 2002

By Brady Huggett

View All Articles by Brady Huggett

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...